Biodexa Pharmaceuticals (BDRX) Non-Interest Income (2014 - 2020)

Biodexa Pharmaceuticals (BDRX) reported Non-Interest Income of $37778.4 for Q3 2020, down 75.1% sequentially from $151749.1 in Q4 2015.

Biodexa Pharmaceuticals (BDRX) Non-Interest Income (2014 - 2020) Analysis & Trends

Biodexa Pharmaceuticals (BDRX) has 3 years of Non-Interest Income data on file, last reported at $37778.4 in Q3 2020.

For the quarter ending Q3 2020, Non-Interest Income changed N/A year-over-year to $37778.4; the trailing twelve-month figure through Sep 2021 stood at $37778.4 (changed 0.0% YoY), and the FY2025 full-year result was -$205.2 million, down 177697.72% from the prior year.
Non-Interest Income fell to $37778.4 in Q3 2020, from $151749.1 in the prior quarter.
In the past five years, Non-Interest Income ranged from a high of $37778.4 in Q3 2020 to a low of $37778.4 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Interest Income (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Biodexa Pharmaceuticals	18.43 Bn	18.43 Bn	-	-

Download Data